Boryung announced it will launch 'Canabjet,' a treatment for hypertension and dyslipidemia, on June 1.
Canabjet is a three-in-one combination drug that combines the angiotensin II receptor blocker (ARB) 'Canab' (active ingredient: Pimasartan) with the HMG-CoA reductase inhibitor 'Atorvastatin' and the cholesterol absorption inhibitor 'Ezetimibe.'
It is intended for patients suffering from both hypertension and dyslipidemia, as well as high-risk patients who have not reached their LDL cholesterol targets with statin monotherapy. It is estimated that over 70% of hypertension patients in South Korea also have dyslipidemia.
Recent treatment guidelines have emphasized the importance of combination therapy for managing both hypertension and dyslipidemia, highlighting the expected benefits of improved treatment convenience and medication adherence through combination drugs.
The need for combination therapy was also discussed at a symposium held by Boryung on May 21 to celebrate the launch of Canabjet. The event featured domestic internists who shared the latest insights on treating hypertension and dyslipidemia, along with practical applications in prescribing.
Lee Chan-joo, a professor of cardiology at Yonsei University College of Medicine, stated, "Pimasartan is a component that has been proven safe and effective across various patient groups. In the context of evolving treatment guidelines that recommend combination therapy, controlling blood pressure and LDL cholesterol through a three-in-one combination drug can help reduce the risk of cardiovascular disease."
Canab is Boryung's 15th domestically developed new drug, launched in 2011. Since then, the company has continued to expand its treatment options with the 'Canab Family' of combination products. The launch of Canabjet marks an extension of its offerings from blood pressure management to high-intensity lipid management.
This year, Boryung aims for sales of the Canab product line to reach 200 billion won. The company is also developing a four-in-one combination drug based on the Canab ingredient, as well as a combination drug for hypertension and diabetes, to build a comprehensive portfolio for chronic diseases.
Sung Baek-min, Executive Director of Boryung's BD & Marketing Division, remarked, "Canabjet is a product developed based on the proven efficacy and safety of Canab. We will lead the market for hypertension and dyslipidemia treatments through data-driven sales and marketing activities."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.